1. Home
  2. Stocks
  3. Cipla Share Price
  • Chart
  • F&O
  • Rating
  • Financials
  • Technicals
  • Volume
  • Result
  • Synopsis
  • Corp Action
  • MF Shareholding
  • Similar Stocks
  • FAQs

    • Cipla Share Price

    Large Cap
    ₹1,671.8
    + 12.4 (0.75%)
    • Advice
    • Hold
    18 September, 2024 02:47 BSE: 500087 NSE: CIPLA ISIN: INE059A01026

    Start SIP in Cipla

    Start SIP

    Cipla Performance

    Day Range

    • Low 1,657
    • High 1,683
    ₹ 1,671

    52 Week Range

    • Low 1,132
    • High 1,683
    ₹ 1,671
    • Open Price1,660
    • Previous Close1,659
    • Volume958137

    Cipla Chart

    • Over 1 Month + 6.07%
    • Over 3 Month + 6.84%
    • Over 6 Month + 12.35%
    • Over 1 Year + 35.31%

    Cipla Key Statistics

    P/E Ratio 31.4
    PEG Ratio 0.8
    Market Cap Cr
    Price to Book Ratio 5
    EPS 50
    Dividend 0.8
    Relative Strength Index 67.86
    Money Flow Index 77.79
    MACD Signal 24.11
    Average True Range 28.42

    Cipla F&O

    Cipla Futures Cipla Option Chain

    Cipla Investment Rating

    • Master Rating:

    • Cipla has an operating revenue of Rs. 26,139.14 Cr. on a trailing 12-month basis. An annual revenue growth of 14% is good, Pre-tax margin of 22% is great, ROE of 15% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 5% and 15% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 4% from the pivot point (which is the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 89 which is a GOOD score indicating consistency in earnings, a RS Rating of 46 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 59 indicates it belongs to a fair industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

    EPS Strength

    Price Strength

    Buyer Demand

    Group Rank

    Cipla Financials
    IndicatorJun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Oper Rev Qtr Cr 3,7523,4454,3814,1673,8583,486
    Operating Expenses Qtr Cr 3,1413,2093,0253,2863,1143,094
    Operating Profit Qtr Cr 1,3608281,3561,3791,205800
    Depreciation Qtr Cr 138137135180136162
    Interest Qtr Cr 5598010
    Tax Qtr Cr 375242363367331206
    Net Profit Qtr Cr 1,0561,0381,1141,030895355
    IndicatorMar 2024Mar 2023
    Total Revenue Annual Cr 17,64516,247
    Operating Expenses Annual Cr 12,09011,998
    Operating Profit Annual in Cr 4,4843,793
    Depreciation Cr 588596
    Interest Annual Cr 2027
    Tax Annual Cr 1,233971
    Net Profit Annual Cr 4,0772,513
    IndicatorMar 2024Mar 2023
    Cash from Operating Activity Annual Cr 3,7273,035
    Cash from Investing Activity Annual Cr -2,883-2,758
    Cash from Financing Annual Activity Cr -709-425
    Net Cash Flow Annual Cr 135-148
    IndicatorMar 2024Mar 2023
    Total ShareHolders Funds Annual Cr 27,97424,638
    Fixed Assets Annual Cr 4,3894,313
    Total Non Current Assets Annual Cr 16,14614,225
    Total Current Assets Annual Cr 14,90713,371
    Total Assets Annual Cr 31,05327,596
    IndicatorMar 2024Mar 2023
    Book Value Per Share Annual Rs 346305
    ROE Annual % 1510
    ROCE Annual % 1815
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 3427
    IndicatorJun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Oper Rev Qtr Cr 6,6256,0826,6046,5896,2695,666
    Operating Expenses Qtr Cr 4,9784,8474,8564,9444,8354,566
    Operating Profit Qtr Cr 1,7161,3161,7481,7341,4941,174
    Depreciation Qtr Cr 247288233290239346
    Interest Qtr Cr 181830261634
    Tax Qtr Cr 435325405438378222
    Net Profit Qtr Cr 1,1789391,0561,131996522
    IndicatorMar 2024Mar 2023
    Total Revenue Annual Cr 26,52123,229
    Operating Expenses Annual Cr 19,48317,726
    Operating Profit Annual in Cr 6,2915,027
    Depreciation Cr 1,0511,172
    Interest Annual Cr 90110
    Tax Annual Cr 1,5471,203
    Net Profit Annual Cr 4,1222,802
    IndicatorMar 2024Mar 2023
    Cash from Operating Activity Annual Cr 4,1343,238
    Cash from Investing Activity Annual Cr -2,988-2,389
    Cash from Financing Annual Activity Cr -1,200-958
    Net Cash Flow Annual Cr -55-109
    IndicatorMar 2024Mar 2023
    Total ShareHolders Funds Annual Cr 26,70623,408
    Fixed Assets Annual Cr 7,6487,270
    Total Non Current Assets Annual Cr 13,27612,188
    Total Current Assets Annual Cr 19,44117,275
    Total Assets Annual Cr 32,71829,463
    IndicatorMar 2024Mar 2023
    Book Value Per Share Annual Rs 332294
    ROE Annual % 1512
    ROCE Annual % 2218
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 2724
    Invest in Cipla

    Cipla Technicals

    EMA & SMA

    Current Price
    ₹1,671.8
    + 12.4 (0.75%)
    pointer
    • Bullish Moving Average
    • ___
    • 16
    • Bearish Moving Average
    • ___
    • 0
    • 20 Day
    • ₹1,627.41
    • 50 Day
    • ₹1,583.35
    • 100 Day
    • ₹1,532.07
    • 200 Day
    • ₹1,446.59
    • 20 Day
    • ₹1,627.89
    • 50 Day
    • ₹1,571.39
    • 100 Day
    • ₹1,518.09
    • 200 Day
    • ₹1,443.36

    Cipla Resistance and Support

    PIVOT
    ₹1,670.5
    Resistance
    First Resistance 1,684.30
    Second Resistance 1,696.80
    Third Resistance 1,710.60
    RSI 67.86
    MFI 77.79
    MACD Single Line 24.11
    MACD 25.12
    Support
    First Support 1,658.00
    Second Support 1,644.20
    Third Supoort 1,631.70

    Cipla Delivery and Volume

    Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
    Day 978,003 59,707,083 61.05
    Week 1,087,476 60,006,926 55.18
    1 Month 1,291,233 70,501,329 54.6
    6 Month 1,872,452 99,502,120 53.14

    Cipla Result Highlights

    Cipla Synopsis

    NSE-Medical-Generic Drugs

    Cipla is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 16574.34 Cr. and Equity Capital is Rs. 161.47 Cr. for the Year ended 31/03/2024. Cipla Ltd. is a Public Limited Listed company incorporated on 17/08/1935 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24239MH1935PLC002380 and registration number is 002380.
    Market Cap 134,008
    Sales 17,584
    Shares in Float 55.72
    No of funds 1101
    Yield 0.78
    Book Value 4.79
    U/D Vol ratio 1.5
    LTDebt / Equity
    Alpha 0.09
    Beta 0.29

    Cipla Shareholding Pattern

    Owner NameJun-24Mar-24Dec-23Sep-23
    Promoters 30.91%33.47%33.47%33.47%
    Mutual Funds 17.62%16.83%16.66%16.48%
    Insurance Companies 5.18%5.44%5.34%5.25%
    Foreign Portfolio Investors 27.82%25.82%25.73%25.74%
    Financial Institutions/ Banks 0.1%0.05%0.13%0.04%
    Individual Investors 14.24%14.2%14.33%14.45%
    Others 4.13%4.19%4.34%4.57%

    Cipla Management

    Name Designation
    Dr. Y K Hamied Chairman
    Mr. M K Hamied Vice Chairman
    Mr. Umang Vohra Managing Director & Global CEO
    Ms. Samina Hamied Non Exe.Non Ind.Director
    Mr. S Radhakrishnan Non Exe.Non Ind.Director
    Mr. Ashok Sinha Independent Director
    Mr. P R Ramesh Independent Director
    Mr. Robert Stewart Independent Director
    Dr. Mandar Vaidya Independent Director
    Mr. Adil Zainulbhai Independent Director
    Ms. Punita Lal Independent Director
    Dr. Balram Bhargava Independent Director

    Cipla Forecast

    Price Estimates

    2,000(9.8%)
    1,758(-3.5%)
    1,590(-12.7%)

    Other Analyst Rating

    Cipla Corporate Action

    Date Purpose Remarks
    2024-07-26 Quarterly Results
    2024-05-10 Audited Results & Final Dividend
    2024-01-22 Quarterly Results (Revised) per share(50%)Special Dividend
    2023-10-27 Quarterly Results
    2023-07-26 Quarterly Results
    Date Purpose Remarks
    2024-08-02 FINAL Rs.13.00 per share(650%)Final Dividend
    2023-07-21 FINAL Rs.8.50 per share(425%)Final Dividend
    2022-08-10 FINAL Rs.5.00 per share(250%)Dividend

    Cipla MF Shareholding

    Name Amount(cr)
    HDFC Balanced Advantage Fund Growth 95,391
    Parag Parikh Flexi Cap Regular Growth 75,956
    SBI Equity Hybrid Fund Regular Payout Inc Dist cum Cap Wdrl 73,405
    ICICI Prudential Bluechip Fund Growth 64,223

    About Cipla

    Cipla Ltd. is a pharmaceutical company in India with a strong global presence. With operations in 80 countries and 47 manufacturing facilities, it sells 1500 products in the market. The largest market of Cipla Ltd. is India, followed by Africa and North America.

    The product profile of Cipla Ltd. ranges from drugs in the respiratory, pediatric asthma, nebulisation, anti-retroviral, urology, cardiology, anti-infective, CNS, and several other illnesses and disorders. Cipla's business is divided into three units - Generics and Branded Generics, Specialty and Consumer Health. 

    The Generics and Branded Generics unit contributes around 19% of the pharmaceutical revenues in India. The division has 4,000+ partners covering the entire country and is constantly seeking to expand the product portfolio.

    The Specialty unit focuses on speciality medicines in respiratory, CNS and critical care. This unit's operations are run under Cipla Technologies LLC (CipTec) and have its headquarters in San Diego, California. 

    The Consumer Health Segment focuses on simplifying healthcare and offering simple and over-the-counter solutions to the consumers. A few brands under this business unit are Nicotex, ActivKids ImmunoBoosters, Cofsils, and UnoBiotics.

    Cipla was founded in 1935 in Mumbai as Chemical Industrial & Pharmaceutical Laboratories Ltd. by Khwaja Abdul Hamied. The name of the company was changed to Cipla in 1984. It received a major boost in 1985 when the US FDA approved its bulk drug facility. Cipla went on to launch the world's first oral iron chelator in 1995. 

    The company acquired the South African company Cipla-Medproin in 2013 and entered digital therapeutics by partnering with Wellthy Therapeutics in India and Brandmed in South Africa in 2019.

    In September 2021, Cipla Ltd. subscribed to 5% equity shares (on a fully diluted basis) of Swasth Digital Health Foundation. It is a not-for-profit organisation focused on building digital healthcare infrastructure.

    Shareholding Pattern

    A total of 230 mutual funds invest in Cipla Ltd., with a total holding of 13.91%. The number of FIIs and FPIs that have invested in it is 786, and their total holding amount to 26.64. These figures are as of March 2022.

    The top mutual funds that have invested in Cipla Ltd. are SBI ETF Nifty 50, Baroda BNP Paribas Balanced Advantage Fund Regular Growth, Mirae Asset Healthcare Fund Regular Growth, Franklin India Bluechip Fund-Growth and UTI Nifty ETF.

    Cipla FAQs

    What is Share Price of Cipla ?

    Cipla share price is ₹1,671 As on 18 September, 2024 | 02:33

    What is the Market Cap of Cipla ?

    The Market Cap of Cipla is ₹135009.1 Cr As on 18 September, 2024 | 02:33

    What is the P/E ratio of Cipla ?

    The P/E ratio of Cipla is 31.4 As on 18 September, 2024 | 02:33

    What is the PB ratio of Cipla ?

    The PB ratio of Cipla is 5 As on 18 September, 2024 | 02:33

    Is it the right time to invest in Cipla?

    Cipla may be the correct pick right now for investors searching for value buys of quality stocks with a longer time horizon. Cipla comes with a HOLD recommendation from the analyst. Cipla has a trailing 12-month operating revenue of INR 20,799.29 crore. Annual revenue growth of 11% is strong, the pre-tax margin of 17% is excellent, and ROE of 13% is excellent. The company has a debt-to-equity ratio of 7%, which indicates a stable balance sheet. Institutional holding has gone up in the last reported quarter is a positive sign.

    Is Cipla an Indian company?

    Cipla Limited, headquartered in Mumbai, India, is an Indian multinational pharmaceutical corporation. Cipla primarily produces drugs for the treatment of respiratory, cardiovascular, arthritis, diabetes, weight loss, and depression, as well as other medical disorders.

    Who is the CEO of Cipla?

    Umang Vohra has been the CEO of Cipla since 1 September 2016.

    What is Cipla's stock price CAGR?

    Cipla's stock price CAGR over ten years is 11%, five years is 10%, three years is 20%, and one year is 22% percent.

    How to buy Cipla Ltd. shares?

    You can easily buy the shares of Grasim Industries Ltd. by registering at 5Paisa and setting up a Demat Account in your name to start trading.

    Q2FY23
    Open Free Demat Account

    Be a part of 5paisa community - The first listed discount broker of India.

    +91
     
    footer_form

    CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI-registered Mutual Fund Distributor | AMFI REGN No.: ARN-104096 | Date of initial Registration: 30/07/2015 | Current validity of ARN : 29/07/2024 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

    *Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Flat fee of Rs. 10/order is available with Power Investor & Ultra Trader Packs. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of Rs.10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

    Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support Desk Helpline: 8976689766

    Contact Us

    Attention Investors

    • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
    • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
    • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

    Email: support@5paisa.com

    Support Desk Helpline: 8976689766

    ©2024, 5Paisa Capital Ltd. All Rights Reserved. We are ISO 27001:2013 Certified.